Initially Diagnosed:
2013
Current Diagnosis:
High Risk Smoldering Multiple Myeloma, MRD-
Treatments Received:
Teclistamab
Mark was diagnosed with smoldering multiple myeloma (SMM) in 2013, a precursor condition to active myeloma that is asymptomatic. He has been closely monitored since being diagnosed, which was, and still is, standard practice for SMM patients. Around the end of 2023, he transitioned to high risk smoldering myeloma (HRSMM), which has a 50% chance of progressing to active myeloma within 2 years. Mark then began talking to his hematologist and researching clinical trials. In November 2024, he started the Immuno-PRISM trial at Dana Farber that is testing the bispecific antibody Teclistamab for HRSMM patients. As of April 2025, he is MRD-. Mark feels very fortunate that his diagnosis and treatment did not come as a surprise and he was able to actively manage his form of the disease and preserve his quality of life. He is very grateful to the clinicians, researchers, and organizations that have advanced the knowledge of the disease and treatment options available to multiple myeloma patients. He has seen tremendous progress since being diagnosed and wants to give back and share his experience, feeling others may benefit from his journey.
